Polyrizon reports successful biocompatibility results for NASARIXTM nasal spray, meeting safety criteria for seasonal allergy relief.
Quiver AI Summary
Polyrizon Ltd., a biotech company based in Raanana, Israel, announced the successful completion of its biocompatibility evaluation for the NASARIXTM Allergy Blocker nasal spray, which met all necessary biological safety criteria. The evaluation followed international standards for medical device safety including ISO 10993 and FDA guidelines, assessing both short-term and long-term safety aspects. NASARIXTM is designed as a drug-free solution to mitigate the effects of seasonal allergies by creating a barrier within the nasal cavity. The results mark a significant milestone in Polyrizon's development of this product and enhance its non-clinical safety profile as the company moves forward with clinical and regulatory processes toward commercialization.
Potential Positives
- Successful completion of the biocompatibility evaluation program for NASARIXTM Allergy Blocker nasal spray, meeting all biological safety tests' acceptance criteria, which bodes well for future product development.
- Evaluation conducted in accordance with internationally recognized standards (ISO 10993, FDA guidance), enhancing credibility and regulatory compliance of the product.
- Positive safety profile of NASARIXTM is supported by extensive toxicological assessments, potentially advancing the product toward commercialization.
- Strategic milestone achieved in product development that strengthens the non-clinical package, indicating significant progress in the company's overall development program for seasonal allergy management.
Potential Negatives
- The company is in the development stage, which typically entails high risks and uncertainty regarding the successful commercialization of its products.
- The press release heavily relies on forward-looking statements, which carry inherent risks and uncertainties that could lead to actual results diverging significantly from expectations.
- The company has not provided specific timelines or milestones for the advancement of NASARIXTM, which can raise concerns for investors about the clarity of its development pathway.
FAQ
What is NASARIXTM and its purpose?
NASARIXTM is a drug-free nasal spray designed to reduce exposure to airborne allergens causing seasonal allergic rhinitis.
What successful results did Polyrizon announce?
Polyrizon announced successful results from the biocompatibility evaluation of NASARIXTM, meeting all biological safety test criteria.
How was the biocompatibility evaluation conducted?
The evaluation was conducted following internationally recognized standards, including ISO 10993 and FDA guidance for medical device safety.
What technology does Polyrizon use in NASARIXTM?
Polyrizon uses its proprietary Capture and Contain TM hydrogel technology to create a protective barrier in the nasal cavity.
What does the successful evaluation mean for NASARIXTM?
The successful evaluation strengthens NASARIXTM's safety profile, supporting its advancement toward potential commercialization as a nasal barrier technology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PLRZ Insider Trading Activity
$PLRZ insiders have traded $PLRZ stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $PLRZ stock by insiders over the last 6 months:
- TOMER IZRAELI (Chief Executive Officer) has made 0 purchases and 2 sales selling 4,400 shares for an estimated $48,435.
- OZ ADLER sold 3,292 shares for an estimated $39,668
- TIDHAR TURGEMAN (Chief Technology Officer) sold 2,917 shares for an estimated $31,795
- LIRON CARMEL has made 0 purchases and 2 sales selling 1,042 shares for an estimated $12,743.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$PLRZ Hedge Fund Activity
We have seen 3 institutional investors add shares of $PLRZ stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FNY INVESTMENT ADVISERS, LLC added 24,575 shares (+inf%) to their portfolio in Q1 2026, for an estimated $287,036
- JANE STREET GROUP, LLC removed 14,032 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $163,893
- CITADEL ADVISORS LLC added 10,149 shares (+inf%) to their portfolio in Q1 2026, for an estimated $118,540
- LEGACY WEALTH MANAGMENT, LLC/ID added 1,150 shares (+inf%) to their portfolio in Q1 2026, for an estimated $13,432
- UBS GROUP AG removed 1,025 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $11,972
- CITIGROUP INC removed 12 shares (-92.3%) from their portfolio in Q1 2026, for an estimated $140
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced successful results from its biocompatibility evaluation program for its proprietary NASARIX TM Allergy Blocker nasal spray, with all required biological safety tests meeting their predetermined acceptance criteria.
The comprehensive evaluation program was designed in accordance with internationally recognized standards for biological safety assessment of medical devices, including the ISO 10993 series, FDA guidance, and applicable European regulatory requirements. The program was developed to assess the safety and biocompatibility profile of N ASARIX TM , a drug-free mucoadhesive nasal spray intended to help reduce exposure to airborne allergens associated with seasonal allergic rhinitis.
The completed testing program evaluated key biological safety endpoints identified for the device, including:
- Cytotoxicity
- Sensitization
- Irritation / Intracutaneous Reactivity
- Material-Mediated Pyrogenicity
- Acute Systemic Toxicity
In addition, long-term systemic toxicity was assessed through a toxicological risk assessment conducted in accordance with ISO 10993-17, demonstrating substantial safety margins across the product’s constituent materials under intended conditions of use.
The biocompatibility evaluation was based on the final NASARIX TM product configuration and supported by extensive toxicological assessments of the formulation components, manufacturing processes, packaging materials, and intended patient exposure. According to the Biological Evaluation Plan, the product consists of well-characterized materials with established safety profiles and utilizes a manufacturing process designed to minimize biological risk.
“We are pleased to report the successful completion of the NASARIX TM biocompatibility program,” said Tomer Izraeli, CEO of Polyrizon. “Achieving positive results across all required biological safety assessments represents a significant milestone in our development program and further supports the biocompatibility safety profile of NASARIX TM as we continue advancing its clinical and regulatory pathway.”
The biocompatibility evaluation program was developed under a risk-management framework consistent with ISO 10993-1 and ISO 14971 and included assessment of physical and chemical characteristics, material safety data, toxicological literature, manufacturing controls, and endpoint-specific biological testing.
The successful completion of the biocompatibility program further strengthens the non-clinical package supporting NASARIX TM and represents an important step toward potential commercialization of the product as a novel nasal barrier technology designed to help individuals suffering from seasonal allergies.
About NASARIX TM
NASARIX TM is Polyrizon’s proprietary nasal spray designed to create a protective barrier within the nasal cavity, helping to prevent contact between inhaled allergens and the nasal mucosa. The product is being developed as a non-drug approach for the management of seasonal allergic rhinitis.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM , or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com .
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the the timing and progress of its clinical trials, advancing the clinical and regulatory pathway of NASARIX TM and the potential commercialization of NASARIX TM as a novel nasal barrier technology designed to help individuals suffering from seasonal allergies. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
[email protected]
